19 completed, 4 terminated, 3 not yet recruiting, 1 recruiting. 8 Not applicable, 7 Phase 3, 4 Phase 1, 3 Phase 2, 1 Phase 4.
Follow Taeniasis: new trials by email Literature Review of Taeniasis trials Research Report on Taeniasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oxfendazole in Mild Parenchymal Brain Cysticercosis Oxfendazole single dose, Oxfendazole three doses, albendazole plus praziquantel regime - Brain Cysticercosis | Phase 2 / Phase 3 | Not yet recruiting | Universidad Peruana Cayetano Heredia | 544 | 2026-12-01 | 2026-05-01 |
| The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis Medical TV Drama Episode (House M.D.) - Neurocysticercosis, Health Literacy | Not applicable | Not yet recruiting | Cephas Health Research Initiative Inc, Ibadan, Nigeria | 60 | 2025-12-15 | 2025-12-04 |
| Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis albendazole and praziquantel, Albendazole - Neurocysticercosis | Phase 4 | Not yet recruiting | R-Evolution Worldwide S.r.l. Impresa Sociale | 300 | 2024-06-01 | 2024-04-23 |
| Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study Neurocysticercosis, Tropical Disease | Unknown | All India Institute of Medical Sciences | 1000 | 2021-01-15 | 2021-01-13 | |
| Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia Neurocysticercosis, Taeniosis | Completed | Technical University of Munich | 2921 | 2019-06-01 | 2023-11-30 | |
| Treatment of Patients With Active Neurocysticercosis in Eastern Africa Neurocysticercosis | Completed | Technical University of Munich | 63 | 2019-04-01 | 2023-11-30 | |
| Digital Health Promotion in Iringa, Tanzania Digital health promotion intervention - HIV Infections, Tuberculosis | Not applicable | Completed | University of Oslo | 600 | 2019-04-01 | 2020-11-04 |
| The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania Diagnosis of (Neuro)cysticercosis - Neurocysticercosis, HIV/AIDS | Completed | Technical University of Munich | 2584 | 2018-04-01 | 2023-11-29 | |
| Intestinal Parasites in Inhabitants of Kuyavian-Pomeranian Province in Poland Tests for diagnosis of intestinal parasitic diseases - Intestinal Disease, Parasitic, Chronic Disease | Completed | Nicolaus Copernicus University | 22 | 2018-02-17 | 2020-03-26 | |
| Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) Albendazole and praziquantel, Albendazole and praziquantel placebo - Neurocysticercosis | Phase 3 | Terminated | Universidad Peruana Cayetano Heredia | 107 | 2016-11-14 | 2022-11-16 |
| Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review Cysticercosis | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 | 2016-10-22 | 2021-08-30 | |
| Single Ascending Dose Safety Study of Oxfendazole oxfendazole, placebo - Tenia Solium Infection | Phase 1 | Withdrawn | Johns Hopkins Bloomberg School of Public Health | 2016-08-01 | 2016-08-30 | |
| Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa? Mass drug administration, praziquantel 10mg/kg, Health education - Taenia Solium Infection | Not applicable | Completed | Institute of Tropical Medicine, Belgium | 2900 | 2016-03-01 | 2023-03-01 |
| Treatment of Peri-calcification Edema in Neurocysticercosis (NCC) Acetazolamide, Dexamethasone - Neurocysticercosis | Phase 2 / Phase 3 | Terminated | Universidad Peruana Cayetano Heredia | 4 | 2015-12-04 | 2025-04-01 |
| Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole Oxfendazole, Placebo - Neurocysticercosis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 70 | 2014-11-17 | 2020-11-02 |
| People Presenting With Neurocysticercosis in North America Neurocysticercosis | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 11 | 2014-09-03 | 2018-04-05 | |
| Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT 7 days of albendazole 15 mg/kg/day, 28 days of albendazole 15 mg/kg/day - Neurocysticercosis | Phase 3 | Completed | All India Institute of Medical Sciences | 97 | 2014-03-01 | 2016-01-01 |
| Taenia Solium Control Case Study in Zambia CLTS - Cysticercosis, Helminthiasis | Not applicable | Completed | University of Zambia | 1197 | 2012-04-01 | 2015-02-11 |
| Targeted Screening for Taenia Solium Tapeworms Niclosamide, Community education campaign - Taenia Solium Taeniasis | Not applicable | Completed | Oregon Health and Science University | 1811 | 2011-05-01 | 2014-10-24 |
| EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso Educational package - Cysticercosis | Not applicable | Completed | University of Oklahoma | 58 | 2011-02-21 | 2018-04-03 |
Showing 20 of 29. Sign in to see all of them.
Neurocysticercosis (20) · Cysticercosis (9) · Epilepsy (6) · Seizures (5) · Cestode Infections (4) · Hydrocephalus (2) · Intestinal Diseases, Parasitic (2) · Neuroinflammatory Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Ascariasis (1) · Chronic Disease (1) · Communicable Diseases (1) · Cryptosporidiosis (1) · Cysts (1)
Infections (29) · Helminthiasis (28) · Parasitic Diseases (28) · Cestode Infections (25) · Nervous System Diseases (22) · Central Nervous System Diseases (21) · Central Nervous System Helminthiasis (20) · Central Nervous System Infections (20) · Central Nervous System Parasitic Infections (20) · Cysticercosis (17) · Pathological Conditions, Signs and Symptoms (9) · Brain Diseases (8) · Pathologic Processes (5) · Signs and Symptoms (5)
Albendazole (8) · Praziquantel (4) · Dexamethasone (3) · oxfendazole (3) · Niclosamide (2) · Acetazolamide (1) · Educational Status (1) · Mass Drug Administration (1) · Omeprazole (1) · Phenytoin (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Universidad Peruana Cayetano Heredia (4) · Technical University of Munich (3) · All India Institute of Medical Sciences (2) · National Institute of Mental Health (NIMH) (2) · Cephas Health Research Initiative Inc, Ibadan, Nigeria (1) · Columbia University (1) · Institute of Tropical Medicine, Belgium (1) · Johns Hopkins Bloomberg School of Public Health (1) · Johns Hopkins University (1) · Nicolaus Copernicus University (1) · Oregon Health and Science University (1) · R-Evolution Worldwide S.r.l. Impresa Sociale (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University of Oklahoma (1)
Peru (7) · United States (6) · Tanzania (3) · Zambia (3) · Burkina Faso (1) · Ecuador (1) · India (1) · Poland (1)
Hector H. Garcia, MD, PhD (2) · Masahiro Fujita, M.D. (2) · Pierre Dorny, PhD (2) · Ajay Garg, MD DM (1) · Andrea S Winkler, M, PhdD (1) · Armando Gonzalez, DVM PhD (1) · Arunmozhimaran Elavarasi, MD DM (1) · Bernard J Ngowi, MD, PhD (1) · Chummy S. Sikasunge, PhD (1) · Chummy Sikasunge, PhD (1) · E. Javier Pretell, MD (1) · Elise M O'Connell, M.D. (1) · Emmanuel Bottieau, PhD, MD (1) · Evans K. Mwape, MSc (1) · Giveson Zulu, PhD (1)
PMID 18495737, PMID 21332573, PMID 24999157, PMID 26984901, PMID 28569208, PMID 29749279, PMID 30653519, PMID 30745383, PMID 33885369, PMID 35900820, PMID 36961623, PMID 37983246, PMID 8615453, PMID 9364715, PMID 9840607
R01NS054805 (1), R21NS069275 (1)